Skip to main content
Equibles
RYTM logo

RYTM · Rhythm Pharmaceuticals, Inc. · Investor Relations

Track RYTM — free

Use RYTM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RYTM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$115.02 +5.16 (+4.70%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$7.97B
Shares
69.33M
Volume · Nov 13 1.16M Avg daily vol (3M) 997.95K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-03 Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
2026-08-04 Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
2026-08-04 Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
2026-06-15 Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
2026-06-15 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
2026-05-05 Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
2026-04-03 Rhythm Pharmaceuticals Announces Changes to Board of Directors
2026-03-26 Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
2026-03-20 Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
2026-03-16 Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
2026-03-02 Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
2026-02-26 Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
2026-01-09 Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones -- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product revenue of approximately $194 million, approximately 50% increase from FY2024
2025-12-11 Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
2025-11-07 Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE ® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
2025-11-04 Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

Past events

Date Event Type
2026-11-11 Stifel 2026 Healthcare Conference Conference
2026-11-09 Guggenheim 3rd Annual Healthcare Innovation Conference Conference
2026-11-03 Rhythm Pharmaceuticals Q3 2026 Earnings Conference Call Earnings call
2026-09-15 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-09 Wells Fargo 21st Annual Healthcare Conference Conference
2026-08-12 Canaccord Genuity 46th Annual Growth Conference Conference
2026-08-04 Rhythm Pharmaceuticals Q2 2026 Earnings Conference Call Earnings call
2026-06-13 Results from Phase 2 Trial Evaluating Setmelanotide in PWS at Six Months Earnings call
2026-06-08 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-06-04 Jefferies Global Healthcare Conference Conference
2026-05-13 Bank of America Global Healthcare Conference Conference
2026-05-05 Q1 FY2026 Earnings conference call (announced in 8-K) Earnings call
2026-04-16 25th Annual Needham Virtual Healthcare Conference Conference
2026-03-19 IMCIVREE Approved by FDA for Acquired Hypothalamic Obesity Webcast
2026-03-16 Earnings conference call (announced in 8-K) Earnings call
2026-03-02 TD Cowen 46th Annual Health Care Conference Conference
2026-02-26 Q4 Earnings conference call (announced in 8-K) Earnings call
2026-02-11 Guggenheim Emerging Outlook: Biotech Summit 2026 Webcast

Source: https://rhythmtx.com/investors-media/

Key facts CIK 1649904 CUSIP 76243J105 13F (30d) 263 filings 226 filers Visit website Investor relations